Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3) - Wikidata - awgldk - TriplyDB

Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)

Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)

http://www.wikidata.org/entity/Q24529101

about

eCAM benefits from diversity that derives from CAM An Evaluation of the Additive Effect of Natural Herbal Medicine on SARS or SARS-like Infectious Diseases in 2003: A Randomized, Double-blind, and Controlled Pilot Study.Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery.Epicatechins Purified from Green Tea (Camellia sinensis) Differentially Suppress Growth of Gender-Dependent Human Cancer Cell Lines.Antidiabetes and Anti-obesity Activity of Lagerstroemia speciosa.Potential antivirals and antiviral strategies against SARS coronavirus infections.Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery.Tannic acid facilitates expression of the polypyrimidine tract binding protein and alleviates deleterious inclusion of CHRNA1 exon P3A due to an hnRNP H-disrupting mutation in congenital myasthenic syndrome Progress in Anti-SARS Coronavirus Chemistry, Biology and Chemotherapy.The role of cellular oxidoreductases in viral entry and virus infection-associated oxidative stress: potential therapeutic applications.Research progress on theaflavins: efficacy, formation, and preparation.Traditional Chinese medicine herbal extracts of Cibotium barometz, Gentiana scabra, Dioscorea batatas, Cassia tora, and Taxillus chinensis inhibit SARS-CoV replication TBC2target: A Resource of Predicted Target Genes of Tea Bioactive Compounds.

P2860

Q24816765-DD409137-47E3-40F0-A462-1ECCE77194F4 Q30372395-96FAAE8B-0BEC-442E-B8B8-C9971225CFCB Q34218166-92F827F7-E8CB-4CF5-8536-A9C2E32ECEAD Q34667547-9C5347C4-4C40-4722-B135-0CBF3F5F5C11 Q36330780-5249103C-850D-4731-B6A7-7E24C759F318 Q36441511-D3536C2C-06BD-4FCC-AD91-B45EF53DA34C Q36775883-708E6345-8298-48D3-8C3F-C2F09775CE61 Q37128363-61BD5257-CB10-4D63-A533-B33E5CE44E92 Q37283689-9A6EE9EE-B24F-4E9F-8CC0-89C51A6D26A9 Q38547857-67937269-67D8-483E-A76C-18C66FC3CD2D Q38651307-4041B897-B6BF-4943-95C6-B93598A0928C Q39703230-33D2A7EF-058B-4B2C-B5A0-9464504E174F Q52665587-187B5BF0-62EB-46C5-9AB8-C3D4557DD9F4

P2860

Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)

http://www.wikidata.org/entity/Q24529101

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)

@ast

Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)

@en

Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)

@en-gb

Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)

@nl

type

label

Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)

@ast

Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)

@en

Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)

@en-gb

Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)

@nl

prefLabel

Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)

@ast

Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)

@en

Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)

@en-gb

Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)

@nl

P1433

Q24529101-57E265FE-EB6A-4135-A39A-6E9C18B90E1B

P1476

Q24529101-FB71887F-B86E-4907-BB3F-06A7F8CB732D

P2093

Q24529101-0C1FD2B0-02FA-48F2-AC6F-36D0D75CCF65

Q24529101-4E41D922-5FE1-4D34-AC98-374A2DBA17A5

Q24529101-A6311382-99A9-44B3-B8BF-E6D0E8FA3855

Q24529101-B8728EC1-A041-446A-9962-22A70DEE2CB3

Q24529101-E68660C3-F265-4E1C-8EC6-142404BB8483

Q24529101-ECB5B4E7-9D4A-4813-92E3-74B559BE167E

P2860

Q24529101-06A5CAC4-5FF1-4F49-A81C-F9DC7277C242

Q24529101-13544AF0-8E90-431B-AF4D-33BB84D19318

Q24529101-1477B99F-E885-4EE1-88EF-BCB6944868BC

Q24529101-1F082F9E-0F6C-4A2A-82E2-08CA00ACAA60

Q24529101-1FE29B9D-8887-4ED6-A5E3-5C2D02FD5726

Q24529101-255FE889-1EFA-46D4-AC00-7E01F456D8C5

Q24529101-419F4982-0BD1-4E27-A318-322E6856A370

Q24529101-551AAEDD-8355-45D1-9355-1FD4AFC0BFE9

Q24529101-67BC2E0A-C877-456D-9E38-AB28EE84BA9C

Q24529101-6F37F7FB-1A5C-4D12-9BD8-6FF576F8E34B

P304

Q24529101-C5193B91-D850-4704-9121-E378ED4F7C46

P31

Q24529101-AE530813-3573-49DF-BA14-7AA7586C7C2D

P356

Q24529101-639A7DB0-E154-41AA-BAF2-FA95A8886F8F

P433

Q24529101-FB8DE72D-6226-4DCD-B97B-51736036C3B7

P478

Q24529101-FAF2B3DD-7CBE-4E97-A367-DDF979D938BF

P50

Q24529101-7FBAD234-C692-492D-8F8E-F6056DADAE72

P577

Q24529101-2A2B7898-E92C-44FB-BFFC-6E0123218001

P5875

Q24529101-EB05B094-FB04-4CEF-B68B-96E7AC569F1D

P698

Q24529101-396BD173-4B10-4B54-A473-1DD917CA892B

P921

Q24529101-3AB3F01B-CDAA-4143-9A03-AB378F87C920

Q24529101-9dc8a7ca-4ab1-f7b7-304c-6edbc213c4ac

Q24529101-ACB6DF4E-2C92-4FD0-A38C-AB2B5FF4D2E7

P932

Q24529101-0885BD38-BB5B-4A23-BA6B-2141AB3523EF

P356

P1433

Evidence-based Complementary and Alternative Medicine

P1476

Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)

@en

P2093

Chia-Nan Chen

http://www.w3.org/2001/XMLSchema#string

Coney P C Lin

http://www.w3.org/2001/XMLSchema#string

John T-A Hsu

http://www.w3.org/2001/XMLSchema#string

Kuo-Kuei Huang

http://www.w3.org/2001/XMLSchema#string

Po-Huang Liang

http://www.w3.org/2001/XMLSchema#string

Wei-Cheng Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

A novel coronavirus associated with severe acute respiratory syndrome

The Genome sequence of the SARS-associated coronavirus

Inhibition of human and ovine acrosomal enzymes by tannic acid in vitro.

Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins.

Processing of the human coronavirus 229E replicase polyproteins by the virus-encoded 3C-like proteinase: identification of proteolytic products and cleavage sites common to pp1a and pp1ab.

Proteolytic processing at the amino terminus of human coronavirus 229E gene 1-encoded polyproteins: identification of a papain-like proteinase and its substrate.

Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection.

P304

209-215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ECAM/NEH081

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Hsing-Pang Hsieh

P577

2005-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7803904

http://www.w3.org/2001/XMLSchema#string

P698

15937562

http://www.w3.org/2001/XMLSchema#string

P921

severe acute respiratory syndrome-related coronavirus

Theaflavin-3,3'-digallate

severe acute respiratory syndrome coronavirus

P932

1142193

http://www.w3.org/2001/XMLSchema#string